Soluble epoxide hydrolase inhibitors: A patent review

Expert Opinion on Therapeutic Patents

Volumn 20, Issue 7, 2010, Pages 941-956

  Shen, Hong C ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Cardiovascular diseases; Diabetes; EPHX2; Hypertension; Metabolic syndrome; SEH; SEH inhibitors; Soluble epoxide hydrolase

Indexed keywords

1 TRIFLUOROMETHOXYPHENYL 3 (1 ACETYLPIPERIDIN 4 YL)UREA; AMIDE; CARBAMIC ACID DERIVATIVE; CARBOXYLIC ACID DERIVATIVE; CHALCONE DERIVATIVE; EPOXIDE HYDROLASE; EPOXIDE HYDROLASE INHIBITOR; EPOXYICOSATRIENOIC ACID; HYDRAZONE DERIVATIVE; HYDROLASE INHIBITOR; ICOSATRIENOIC ACID; MORPHINE; ROFECOXIB; THIOAMIDE; THIOUREA DERIVATIVE; UNCLASSIFIED DRUG; UREA DERIVATIVE; ENZYME INHIBITOR;

DIABETES MELLITUS; DRUG EFFICACY; DRUG INDICATION; DRUG POTENCY; DYSLIPIDEMIA; ENZYME INHIBITION; EYE DISEASE; HUMAN; HYPERTENSION; IMMUNOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; NEUROLOGIC DISEASE; NEUROPATHIC PAIN; NONHUMAN; PAIN; PATENT; REVIEW; STROKE; STRUCTURE ACTIVITY RELATION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG DELIVERY SYSTEM;

ANIMALS; DRUG DELIVERY SYSTEMS; ENZYME INHIBITORS; EPOXIDE HYDROLASES; HUMANS; PATENTS AS TOPIC;

EID: 77953786534     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.2010.484804     Document Type: Review

References (149)

1. Newman JW, Morisseau C, Hammock BD. Epoxide hydrolases: their roles and interactions with lipid metabolism. Prog Lipid Res 2005;44:1-51
2. Hammock BD, Storms DH, Grant DF. Epoxide hydrolases. In: Guengerich, FP, editior, Comprehensive toxicology. Pergamon, Oxford; 1997. p. 283-305
3. Fretland AJ, Omiecinski CJ. Epoxide hydrolases: biochemistry and molecular biology. Chem Biological Interact 2000;129:41-59
4. Yu Z, Xu F, Huse LM, et al. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ Res 2000;87:992-998
5. Spector AA, Fang X, Snyder GD, et al. Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function. Prog Lipid Res 2004;43:55-90
6. Pacifici GM, Temellini A, Giuliani L, et al. Cytosolic epoxide hydrolase in humans: development and tissue distribution. Arch Toxicol 1988;62:254-257 (Pubitemid 18266672)
7. Larsen BT, Gutterman DD, Hatoum OA. Emerging role of epoxyeicotrienoic acids in coronary vascular function. Eur J Clin Invest 2006;36:293-300
8. Capdevila JH, Falck JR, Harris RC. Cytochrome P450 and arachidonic acid bioactivation: molecular and functional properties of the arachidonate monooxygenase. J Lipid Res 2000;41:163-181
9. Fisslthaler B, Popp R, Kiss L, et al. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature 1999;401:493-497 (Pubitemid 29470209)
10. Larsen BT, Miura H, Hatoum OA, et al. Epoxyeicosatrienoic and dihydroxyeicosatrienoic acids dilate human coronary arterioles via BKca channels: implications for soluble epoxide hydrolase inhibition. Am J Physiol Heart Circ Physiol 2006;290:H491-499
11. Archer SL, Gragasin FS, Wu X, et al. Endothelium-derived hyperpolarizing factor in human internal mammary artery is 11,12-epoxyeicosatrienoic acid and causes relaxation by activating smooth muscle BK (Ca) channels. Circulation 2003;107:769-776
12. Maier KG, Roman RJ. Cytochrome P450 metabolites of arachidonic acid in the control of renal function. Curr Opin Nephrol Hypertens 2001;10:81-87
13. Lin WK, Falck JR, Wong PY. Effects of 14,15-epoxyeicosatrienoic acid infusion on blood pressure in normal and hypertensive rats. Biochem Biophys Res Commun 1990;167:977-981
14. Spiecker M, Liao JK. Vascular protective effects of cytochrome p450 epoxygenase-derived eicosanoids. Arch Biochem Biophys 2005;433:413-420
15. Node K, Huo Y, Ruan X, et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 1999;285:1276-1279
16. Kessler P, Popp R, Busse R, et al. Proinflammatory mediators chronically downregulate the formation of the endothelium-derived hyperpolarizing factor in arteries via a nitric oxide/cyclic GMP-dependent mechanism. Circulation 1999;99:1878-1884
17. Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 2002;82:131-185
18. Nithipatikom K, Moore JM, Isbell MA, et al. Effects of selective inhibition of cytochrome P-450 w-hydroxylases and ischemic preconditioning in myocardial protection. Am J Physiol Heart Circ Physiol 2006;290:H500-505
19. Gross GJ, Hsu A, Flack JR, et al. Mechanisms by which epoxyeicosatrienoic acids (EETs) elicit cardioprotection in rat hearts. J Mol Cell Card 2007;42:687-691
20. Alkayed NJ, Iliff JJ, Zhang W, et al. Compositions and methods for the treatment of disorders associated with abberrant vasodilation. US2009069418; 2009
21. Jung O, Brandes RP, Kim IH, et al. Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension. Hypertension 2005;45:759-765
22. Img JD, Zhao X, Capdevila JH, et al. Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension 2002;39:690-694
23. Imig JD, Zhao X, Zaharis CZ, et al. An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension 2005;46:975-981
24. Available from: http://www. aretetherapeutics.com
25. Gomez GA, Morisseau C, Hammock BD, et al. Human soluble epoxide hydrolase: structural basis of inhibition by 4-(3-cyclohexylureido)- carboxylic acids. Protein Sci 2006;15:58-64
26. Kim IH, Morrisseau C, Watanabe T, et al. Design, synthesis, and biological activity of 1,2-disubstituted ureas as potent inhibitors of the soluble epoxide hydrolase of increased water solubility. J Med Chem 2004;47:2110-2122
27. Kim IH, Heirtzler FR, Morisseau C, et al. Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility. J Med Chem 2005;48:3621-3629
28. Morisseau C, Newman JW, Tsai HJ, et al. Peptidyl-urea based inhibitors of soluble epoxide hydrolases. Bioorg Med Chem Lett 2006;16:5439-5444
29. Li HY, Jin Y, Morisseau C, et al. The 5-substituted piperazine as a novel secondary pharmacophore greatly improving the physical properties of urea-based inhibitors of soluble epoxide hydrolase. Bioorg Med Chem 2006;14:6586-6592
30. Miyamoto T, Silva M, Hammock BD. Inhibition of epoxide hydrolases and glutathione S-transferases by 2,3, and 4-substituted derivatives 4¢-phenylchalcone and its oxide. Arch Biochem Biophys 1987;254:203-213
31. Morisseau C, Goodrow MH, Dowdy D, et al. Potent urea and carbamate inhibitors of soluble epoxide hydrolases. Proc Natl Acad Sci 1999;96:8849-8854
32. Dietze EC, Casas J, Kuwano E, et al. Inhibition of epoxide hydrolase from human, monkey, bovine, rabbit and murine liver by trans-3-phenylglycidols. Comp Biochem Physiol B 1993;104:309-314
33. Shen HC, Ding FX, Deng Q, et al. A strategy of employing aminoheterocycles as amide mimics to identify novel, potent and bioavailable soluble epoxide hydrolase inhibitors. Bioorg Med Chem Lett 2009;19:5716-5721
34. The Regents of the University of California. Recombinant soluble epoxide hydrolase. US005445956; 1995
35. The Regents of the University of California. Epoxide hydrolase complexes and methods therewith. US006150415; 2000
36. The Regents of the University of California. Inhibitors of epoxide hydrolases for the treatment of hypertension. US006531506; 2003
37. The Regents of the University of California. Inhibitors of epoxide hydrolases for the treatment of hypertension. US20030119900; 2003
38. The Regents of the University of California. Inhibitors of epoxide hydrolases for the treatment of hypertension. US20040092487; 2004
39. The Regents of the University of California. Inhibitors of epoxide hydrolases for the treatment of hypertension. US006693130; 2004
40. The Regents of the University of California. Inhibitors of epoxide hydrolases for the treatment of hypertension. US20050282767; 2005
41. The Regents of the University of California. Inhibitors of epoxide hydrolases for the treatment of hypertension. US20060035869; 2006
42. The Regents of the University of California. Improved inhibitors for the soluble epoxide hydrolase. WO2006045119; 2006
43. The Regents of the University of California. Improved inhibitors for the soluble epoxide hydrolase. WO2004089296; 2004
44. Morisseau C, Goodrow MH, Dowdy D, et al. Potent urea and carbamate inhibitors of soluble epoxide hydrolases. Proc Natl Acad Sci USA 1999;96:8849-8854
45. The Regents of the University of California. Inhibitors for the soluble epoxide hydrolase. US20050164951; 2005
46. The Regents of the University of California. Inhibitors for the soluble epoxide hydrolases US20050026844; 2005
47. The Regents of the University of California. Inhibitors of epoxide hydrolases. US20090326039; 2009
48. The Regents of the University of California. Piperidinyl, indolyl, pyridinyl, morpholinyl and benzimidazolyl urea derivatives as inhibitors of soluble epoxide hydrolase for the treatment of hypertension, inflammations and other diseases. WO2007106525; 2007
49. The Regents of the University of California. Conformationally restrained urea inhibitors of soluble epoxide hydrolase. US20070225283; 2007
50. Hwang SH, Tsai HJ, Liu JY, et al. Orally bioavailable potent soluble epoxide hydrolase inhibitors. J Med Chem 2007;50:3825-3840
51. The Regents of the University of California. Preparation of novel 1,3-substituted ureas as inhibitors of soluble epoxide hydrolase. WO2009020960; 2009
52. The Regents of the University of California. Use of inhibitors of epoxide hydrolases to inhibit vascular smooth muscle cell proliferation. US20030139469; 2003
53. The Regents of the University of California. Use of inhibitors of epoxide hydrolases to inhibit vascular smooth muscle cell proliferation. WO2003061597; 2003
54. The Regents of the University of California. Inhibitors of epoxide hydrolases for the treatment of inflammation. US20070117782; 2007
55. The Regents of the University of California. Use of cis- epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to reduce cardiomyopathy. US20090216318; 2009
56. The Regents of the University of California. Use of cis- epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to reduce damage from stroke. US20060148744; 2006
57. The Regents of the University of California. Use of cis- epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to reduce pulmonary infiltration by neutrophils. US20050222252; 2005
58. The Regents of the University of California. Use of cis- epoxyeicosantrienoic acids and inhibitors of soluble epoxide hydrolase to reduce pulmonary infiltration by neutrophiles. WO2005094373; 2005
59. The Regents of the University of California. Use of cis- epoxyeicosantrienoic acids and inhibitors of soluble epoxide hydrolase to reduce pulmonary infiltration by neutrophiles. US20050222252; 2005
60. The Regents of the University of California. Treating pulmonary diseases mediated by polyunsaturated lipid metabolites and assays for epoxide hydrolase inhibitors. EP 0 926 951. WO1998006261; 1998
61. The Regents of the University of California. Epoxide hydrolase inhibitor methods. US006174695; 2001
62. The Regents of the University of California. Alleviating neuropathic pain with EETs and sEH inhibitors. WO2009062073; 2009
63. The Regents of the University of California. Use of inhibitors of soluble epoxide hydrolase to synergize activity of COX and 5-LOX inhibitors. WO2006086168; 2006
64. The Regents of the University of California. Use of inhibitors of soluble epoxide hydrolase to synergize activity of COX and 5-LOX inhibitors. US20060178347; 2006
65. The Regents of the University of California. Use of sEH inhibitors as analgesics. WO2007022509; 2007
66. The Regents of the University of California. Use of sEH inhibitors as analgesics. US20080249055; 2008
67. The Regents of the University of California. Use of cis- epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to alleviate eye disorders. WO2007009001; 2007
68. The Regents of the University of California. Use of cis- epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to alleviate eye disorders. US20080279912; 2008
69. The Regents of the University of California. Use of cis- epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to treat conditions mediated by PBR, CB2 and NK2 receptors. WO2008073130; 2008
70. The Regents of the University of California. Use of soluble hydrolase inhibitors in the treatment of mooth muscle disorders. US20090270452; 2009
71. The Regents of the University of California. Soluble epoxide hydrolase inhibitors for the treatment of endothelial dysfunction. WO2009086426; 2009
72. The Regents of the University of California. Soluble epoxide hydrolase inhibitors for the treatment of rheumatoid arthritis. US2008058033; 2008
73. Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors for the treatment of rheumatoid arthritis. US20080221104; 2008
74. The Regents of the University of California. Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids. US20090018092; 2009
75. The Regents of the University of California. Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids. WO2005089380; 2005
76. The Regents of the University of California. Inhibition of phosphatase activity of soluble epoxide hydrolase amino terminus and uses thereof. WO2007022059; 2007
77. The Regents of the University of California. Inhibition of phosphatase activity of soluble epoxide hydrolase amino terminus and uses thereof. US20090215894; 2009
78. Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors. WO20080076770; 2008
79. Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors. WO2008039794; 2008
80. Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors. WO2008040000; 2008
81. Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors. US20080207621; 2008
82. Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors. WO2008039999; 2008
83. Arete Therapeutics, Inc. 4-Piperidinylurea compounds as soluble epoxide hydrolase inhibitors. WO2008112022; 2008
84. Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors. WO2008116145; 2008
85. Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors. US20090082350; 2009
86. Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors. US2009035949; 2009
87. Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors. US20090023731; 2009
88. Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors. US20080227780; 2008
89. Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors. WO2008051873; 2008
90. Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors. US20080200444; 2008
91. Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors. US20080221100; 2008
92. Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors. WO2008051875; 2008
93. Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors. WO2009129508; 2009
94. Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors. WO2009035928; 2009
95. Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors. US2009270382; 2009
96. Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors. US20080200467; 2008
97. Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors. WO2008073623; 2008
98. Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors. US20090082456; 2009
99. Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors. WO2009035927; 2009
100. Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors. WO2009082423; 2009
101. Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors. WO2008016884; 2008
102. Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors. US20080032978; 2008
103. Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors. WO2009035951; 2009
104. Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors. US20090082395; 2009
105. Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors. WO2009086429; 2009
106. Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors for the treatment of endothelial dysfunction. WO20090247521; 2009
107. Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors for treatment of metabolic syndrome and related disorders. US20080221105; 2008
108. Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors for treatment of metabolic syndrome and related disorders. US20090197916; 2009
109. Boehringer Ingelheim Pharmaceuticals, Inc. Method of treating immunological disorders mediated by T-lymphocytes. WO0023060; 2000
110. Boehringer Ingelheim Pharmaceuticals, Inc. Methods of using soluble epoxide hydrolase inhibitors. WO03002555; 2003
111. Boehringer Ingelheim. Method of using soluble epoxide hydrolase inhibitors. US20030022929; 2003
112. Boehringer Ingelheim. Method of using soluble epoxide hydrolase inhibitors. US006831082; 2004
113. Boehringer Ingelheim. Methods of using soluble epoxide hydrolase inhibitors US20040092567; 2004
114. Boehringer Ingelheim. Methods of USing soluble epoxide hydrolase inhibitors US006890925; 2005
115. Boehringer Ingelheim Pharma GMBH & Co. KG. Substituted pyrazole compounds useful as soluble epoxide hydrolase inhibitors. WO2007067836; 2007
116. Boehringer Ingelheim USA Corporation. Substituted pyrazole compounds useful as soluble epoxide hydrolase inhibitors. US20090227588; 2009
117. Boehringer Ingelheim Pharma GMBH & Co. KG. Soluble epoxide hydrolase inhibitors and methods of using same. WO2006121719; 2006
118. Boehringer Ingelheim Corporation. Soluble epoxide hydrolase inhibitors and methods of using same. US20060276515; 2006
119. Boehringer Ingelheim. N-Substituted pyridinone or pyrimidinone compounds useful as soluble epoxide hydrolase inhibitors. WO2007044491; 2007
120. Boehringer Ingelheim USA Corporation. N-Substituted pyridinone or pyrimidinone compounds useful as soluble epoxide hydrolase inhibitors. US20080280904; 2008
121. Boehringer Ingelheim. Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors. WO2007098352; 2007
122. Boehringer Ingelheim International GMBH. Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors. US20090099184; 2009
123. Boehringer Ingelheim Pharma GMBH & Co. KG. Methods of using aryl sulfonyl compounds effective as soluble epoxide hydrolase inhibitors. WO2008022171; 2008
124. Boehringer Ingelheim USA Corporation. Methods of using aryl sulfonyl compounds effective as soluble epoxide hydrolase inhibitors. US20100016310; 2010
125. Boehringer Ingelheim Pharma GMBH & Co. KG. Soluble epoxide hydrolase inhibitors and methods of using same. US20090111791; 2009
126. Boehringer Ingelheim Pharma GMBH & Co. KG. Cyclic urea compounds as soluble epoxide hydrolase inhibitors effective for the treatment of cardiovascular disorders. WO2007106706; 2007
127. Boehringer Ingelheim Pharma GMBH & Co. KG. Soluble epoxide hydrolase inhibitors and methods of using same. WO2007106705; 2007
128. Boehringer Ingelheim Pharma GMBH & Co. KG. Methods of using acyl hydrazones as sEH inhibitors. WO2006121684; 2006
129. Boehringer Ingelheim Corporation. Methods of using acyl hydrazones as sEH inhibitors. US20060293292; 2006
130. Boehringer Ingelheim. Fluorescence polarization assay. US20030082665; 2003
131. Boehringer Ingelheim. Fluorescence polarization assay. WO2002082082; 2002
132. Taisho Pharmaceutical Co. JP126454; 2007
133. Taisho Pharmaceutical Co. 2-Thienylurea derivative. WO2007043652; 2007
134. Taisho Pharmaceutical Co. Benzimidazole-5-carboxamide derivative. WO2007043653; 2007
135. Merck & Co Inc. Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment. WO2009011872; 2009
136. Merck & Co Inc. Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment. WO2009111207; 2009
137. SmithKline Beecham Corporation. Novel sEH inhibitors and their use. WO2008105968; 2008
138. SmithKline Beecham Corporation. Novel sEH inhibitors and their use. WO2009097476; 2009
139. SmithKline Beecham Corporation. Novel sEH inhibitors and their use. WO2009049165; 2009
140. SmithKline Beecham Corporation. Novel sEH inhibitors and their use. WO2009097474; 2009
141. SmithKline Beecham Corporation. Novel sEH inhibitors and their use. WO2009049157; 2009
142. SmithKline Beecham Corporation. Novel sEH inhibitors and their use. WO2009049154; 2009
143. SmithKline Beecham Corporation. Novel sEH inhibitors and their use. WO2009073772; 2009
144. SmithKline Beecham Corporation. Novel sEH inhibitors and their use. WO2009049157; 2009
145. SmithKline Beecham Corporation. sEH and 11 beta-HSD1 inhibitors and their use. WO2009070497; 2009
146. GlaxoSmithKline LLC. sEH and 11 beta-HSD1 inhibitors. WO2010011917; 2010
147. Roche Palo Alto LLC. Methods of treating genitourinary disorder using inhibitors of soluble epoxide hydrolase. US2009082402; 2009
148. Available from: http://www. aretetherapeutics.com
149. Imig JD, Hammock BD. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov 2009;8:794-805